Beloranib

DB12671InvestigationalSmall molecule

Beloranib has been used in trials studying the treatment of Obesity, Over-weight, Type 2 Diabetes, Craniopharyngioma, and Hypothalamic Injury, among others.

Mechanism: Pharmacologically active on Methionine aminopeptidase 2
Curator reviewed
Formula / weight: C₂₉H₄₁NO₆ · 499.648 g/mol (avg)
Code names: CKD-732 · ZGN-433 · ZGN-440

Resolves to

Compound

UNIIFI471K8BU6CAS251111-30-5PubChem6918502

Structure

InChIKeyZEZFKUBILQRZCK-MJSCXXSSSA-NSMILESCO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C1=CC=C(OCCN(C)C)C=C1

Targets

P50579METAP2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

48Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Beloranib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account